Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

Jennifer A. Kanakry, Yvette L. Kasamon, Javier Bolaños-Meade, Ivan M. Borrello, Robert A. Brodsky, Ephraim J. Fuchs, Nilanjan Ghosh, Douglas E. Gladstone, Christopher D. Gocke, Carol Ann Huff, Christopher G. Kanakry, Leo Luznik, William Matsui, Huzefa J. Mogri, Lode J. Swinnen, Heather J. Symons, Richard J. Jones, Richard F. Ambinder

Research output: Contribution to journalArticle

Abstract

Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

Original languageEnglish (US)
Pages (from-to)1514-1517
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number10
DOIs
StatePublished - Oct 1 2013

Keywords

  • Allogeneic blood or marrow transplantation
  • Graft-versus-host disease prophylaxis
  • Post-transplantation cyclophosphamide
  • Post-transplantation lymphoproliferative disorder

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis'. Together they form a unique fingerprint.

  • Cite this